|
Company:
|
EXELIXIS, INC. (EXEL)
|
|
Form Type:
|
8-K
|
|
Filing Date:
|
5/11/2021
|
|
CIK:
|
0000939767
|
|
Address:
|
1851 HARBOR BAY PARKWAY
|
|
City, State, Zip:
|
ALAMEDA, California 94502
|
|
Telephone:
|
(650) 837-7000
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$17.55
|
Change:
-0.06 (-0.34%)
|
Trade Time:
Feb 03
|
Market Cap:
$5.66B
|
|
|
|
|
|
|
Description of Business
|
|
Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology
company that strives to accelerate the discovery, development and
commercialization of new medicines for difficult-to-treat cancers. Using our
considerable drug discovery, development and commercialization resources and
capabilities, we have invented and brought to market innovative therapies that
appropriately balance patient benefits and risks; we will continue to build on
this foundation as we strive to provide cancer patients with new treatment
options that improve upon current standards of care.
Today, four products that originated in Exelixis laboratories are available to
be prescribed to patients. Sales related to our flagship molecule, cabozantinib,
account for the large majority of our revenues. Cabozantinib is an inhibitor of
multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has
been approved by the U.S.
|
|
|
|